Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1975 Aug;8(2):164–171. doi: 10.1128/aac.8.2.164

Susceptibilities of Gram-Negative Bacteria to Combinations of Antimicrobial Agents In Vitro

Bernard Leng a,1, Burt R Meyers a, Shalom Z Hirschman a, Gerald T Keusch a
PMCID: PMC429284  PMID: 810077

Abstract

Combinations of either clindamycin or erythromycin with gentamicin, colimycin, or carbenicillin were studied for their antimicrobial effects on clinical isolates of Escherichia coli, Klebsiella sp., Proteus mirabilis, Serratia marcescens, Enterobacter aerogenes, and Pseudomonas aeruginosa. No antagonistic effects of the antibiotic combinations were observed. Synergistic effects of the antibiotic combinations were noted against most strains of E. coli tested, especially when either clindamycin or erythromycin was combined with gentamicin or colimycin. Of 16 other combinations of antibiotics examined with strains of E. coli as the test organisms, only the combination of penicillin G with either gentamicin or colimycin showed consistent synergy. The marked synergy of clindamycin combined with either gentamicin or colimycin was further demonstrated by following the kinetics of the bactericidal action of the antibiotic combinations and the effects on bacterial protein synthesis.

Full text

PDF
164

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altemeier W. A., Todd J. C., Inge W. W. Gram-negative septicemia: a growing threat. Ann Surg. 1967 Oct;166(4):530–542. doi: 10.1097/00000658-196710000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bryant R. E., Hood A. F., Hood C. E., Koenig M. G. Factors affecting mortality of gram-negative rod bacteremia. Arch Intern Med. 1971 Jan;127(1):120–128. [PubMed] [Google Scholar]
  3. FINLAND M., JONES W. F., Jr, BARNES M. W. Occurrence of serious bacterial infections since introduction of antibacterial agents. J Am Med Assoc. 1959 Aug 29;170:2188–2197. doi: 10.1001/jama.1959.63010180008012. [DOI] [PubMed] [Google Scholar]
  4. Fass R. J., Rotilie C. A., Prior R. B. Interaction of clindamycin and gentamicin in vitro. Antimicrob Agents Chemother. 1974 Nov;6(5):582–587. doi: 10.1128/aac.6.5.582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Freid M. A., Vosti K. L. The importance of underlying disease in patients with gram-negative bacteremia. Arch Intern Med. 1968 May;121(5):418–423. [PubMed] [Google Scholar]
  6. Heman-Ackah S. M., Garrett E. R. Kinetics and mechanisms of drug action on microorganisms. 13. Comparative studies on action of lincomycin, clindamycin, and U 24729A against Escherichia coli. J Med Chem. 1972 Feb;15(2):152–163. doi: 10.1021/jm00272a009. [DOI] [PubMed] [Google Scholar]
  7. Hodgin U. G., Sanford J. P. Gram-negative rod bacteremia. An analysis of 100 patients. Am J Med. 1965 Dec;39(6):952–960. doi: 10.1016/0002-9343(65)90118-x. [DOI] [PubMed] [Google Scholar]
  8. Levine A. S., Schimpff S. C., Graw R. G., Jr, Young R. C. Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol. 1974 Apr;11(2):141–202. [PubMed] [Google Scholar]
  9. Martin C. M., Cuomo A. J., Geraghty M. J., Zager J. R., Mandes T. C. Gram-negative rod bacteremia. J Infect Dis. 1969 Apr-May;119(4):506–517. doi: 10.1093/infdis/119.4-5.506. [DOI] [PubMed] [Google Scholar]
  10. Meyers B. R., Hirschman S. Z. Tobramycin: in vitro antibacterial spectrum of a new aminoglycoside. J Clin Pharmacol New Drugs. 1972 Aug-Sep;12(8):313–320. doi: 10.1002/j.1552-4604.1972.tb00173.x. [DOI] [PubMed] [Google Scholar]
  11. Rosdahl N., Thomsen V. F. In vitro activity of gentamicin, alone and in combination with other antibiotics. Acta Pathol Microbiol Scand B Microbiol Immunol. 1971;79(3):333–342. doi: 10.1111/j.1699-0463.1971.tb00069.x. [DOI] [PubMed] [Google Scholar]
  12. Sande M. A., Overton J. W. In vivo antagonism between gentamicin and chloramphenicol in neutropenic mice. J Infect Dis. 1973 Aug;128(2):247–250. doi: 10.1093/infdis/128.2.247. [DOI] [PubMed] [Google Scholar]
  13. Tanaka K., Teraoka H., Nagira T., Tamaki M. [14C]erythromycin-ribosome complex formation and non-enzymatic binding of aminoacyl-transfer RNA to ribosome-messenger RNA complex. Biochim Biophys Acta. 1966 Aug 17;123(2):435–437. doi: 10.1016/0005-2787(66)90300-5. [DOI] [PubMed] [Google Scholar]
  14. Teraoka H., Tanaka K., Tamaki M. The comparative study on the effects of chloramphenicol, erythromycin and lincomycin on polylysine synthesis in an Escherichia coli cell-free system. Biochim Biophys Acta. 1969 Feb 18;174(2):776–778. doi: 10.1016/0005-2787(69)90312-8. [DOI] [PubMed] [Google Scholar]
  15. Vazquez D. Binding of chloramphenicol to ribosomes. The effect of a number of antibiotics. Biochim Biophys Acta. 1966 Feb 21;114(2):277–288. doi: 10.1016/0005-2787(66)90309-1. [DOI] [PubMed] [Google Scholar]
  16. Won C. M., Garrett E. R. Kinetics and mechanisms of action of drugs on microorganisms. XVI. Effect of oleandomycin and its combinations with tetracycline, chloramphenicol, erythromycin, lincomycin, and 1'-demethyl-4'-depropyl-4'-(R and S)-n-pentylclindamycin on microbial generation of Escherichia coli. J Pharm Sci. 1973 Jul;62(7):1087–1092. doi: 10.1002/jps.2600620707. [DOI] [PubMed] [Google Scholar]
  17. YOW E. M. Clinical significance of rising incidence of infections due to gram-negative bacilli. Postgrad Med. 1955 May;17(5):413–419. doi: 10.1080/00325481.1955.11708216. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES